Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sirnaomics Ltd. ( (HK:2257) ) has provided an announcement.
Sirnaomics Ltd. has announced its unaudited condensed consolidated interim results for the six months ending June 30, 2025. The interim results, which comply with the Hong Kong Stock Exchange’s listing rules, will be available on the company’s website and dispatched to shareholders in early September 2025. This announcement reflects the company’s commitment to transparency and regulatory compliance, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.
More about Sirnaomics Ltd.
Sirnaomics Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development of RNAi therapeutics. It operates within the pharmaceutical industry and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 782,390
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.05B
For a thorough assessment of 2257 stock, go to TipRanks’ Stock Analysis page.